Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(25%)
Results Posted
300%(3 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_3
1
25%
Ph phase_1
3
75%

Phase Distribution

3

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (75.0%)
Phase 31 (25.0%)

Trials by Status

terminated250%
active_not_recruiting125%
completed125%

Recent Activity

1 active trials
Showing 4 of 4
active_not_recruitingphase_3

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

NCT05059522
terminatedphase_1

Rituximab + Immunotherapy in Follicular Lymphoma

NCT03636503
terminatedphase_1

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

NCT02554812
completedphase_1

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

NCT02315066

Clinical Trials (4)

Showing 4 of 4 trials
NCT05059522Phase 3

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Active Not Recruiting
NCT03636503Phase 1

Rituximab + Immunotherapy in Follicular Lymphoma

Terminated
NCT02554812Phase 1

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

Terminated
NCT02315066Phase 1

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4